The Share

The Diamyd Medical share is traded on Nasdaq First North Growth Market (ticker : DMYD B). ISIN code: SE0005162880.

About Nasdaq First North Growth Market

Nasdaq First North Growth Market is an alternative marketplace operated by an exchange within the Nasdaq Group. Companies on Nasdaq First North Growth Market are not subject to the same rules as companies on the regulated main market. Instead they are subject to a less extensive set of rules and regulations adjusted to small growth companies. The risk in investing in a company on Nasdaq First North Growth Market may therefore be higher than investing in a company on the main market. All companies with shares traded on Nasdaq First North Growth Market have a Certified Adviser who monitors that the rules are followed. The Exchange approves the application for admission to trading.

Certified Adviser at Nasdaq First North Growth Market

FNCA Sweden AB, Humlegårdsgatan 5, Box 5807, SE-102 48 Stockholm. Tel: 08-528 00 399, E-mail: info@fnca.se.

Annual Report

  December 17, 2019

Company Presentation

CEO Comments

Read More
  Quarterly Report 2 19/20, March 25, 2020

Dear Shareholders and readers

The last weeks we have seen the Corona virus disease (COVID-19) outbreak creating turmoil in the financial markets and affecting the global economy. Given the prevailing times, we are fortunate at Diamyd Medical to have solid finances and a strong position with the diabetes vaccine Diamyd®, our lead candidate.
Given the prevailing times, we are fortunate at Diamyd Medical to have solid finances and a strong position with the diabetes vaccine Diamyd®, our lead candidate.
Ulf Hannelius, President and CEO

Calendar

  
June 4, 2020
Erik Penser Bank Corporate Market Day
Company presentation by CEO Ulf Hannelius.
Live broadcast at 12:30 CET
June 24, 2020
Quarterly Report III
Quarterly Report 3 2019/2020
October 7, 2020
Year-End Report
Year-End Report 2019/2020
 

We are dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in medical and stem cell technologies

 

Ten largest shareholders as of March 31, 2020

ShareholderA SharesB SharesCapital %Votes %
Avanza Pension 9 391 264 13.58 10.19
Essen-Möller, Anders 2 556 223 6 333 040 12.85 34.60
Lindkvist, Bertil 6 440 000 9.31 6.99
Nordnet Pension 2 256 097 3.26 2.45
Swedbank Försäkring 1 026 873 1.48 1.11
Hansen, Patrik 750 000 1.08 0.81
Konstruktions o Försäljningsaktiebolag 750 000 1.08 0.81
Arandi Development AB 500 000 0.72 0.54
Schelé, Sven 485 000 0.70 0.53
Relbo AB 475 550 0.69 0.52
Remaining shareholders 38 205 749 55.23 41.45
Total 2 556 223 66 613 573 100.0 100.0

Order GAD for preclinical research

ORDER

Annual Report

  December 17, 2019
Annual Report cover image
Download

Contact Us

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden
+46 8 661 00 26
+46 8 661 63 68

Subscribe

   

Follow Us

  ©
GAD PRODUCTS
Order GAD for preclinical research